ESTRELLA IMMUNOPHARMA INC (ESLA) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ESLA • US2975841048

1.3 USD
-0.08 (-5.8%)
Last: Feb 11, 2026, 04:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

0

ESLA gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. ESLA has a bad profitability rating. Also its financial health evaluation is rather negative. ESLA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ESLA has reported negative net income.
  • ESLA had a negative operating cash flow in the past year.
  • ESLA had negative earnings in each of the past 5 years.
  • In the past 5 years ESLA always reported negative operating cash flow.
ESLA Yearly Net Income VS EBIT VS OCF VS FCFESLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -383.16%, ESLA is doing worse than 92.93% of the companies in the same industry.
Industry RankSector Rank
ROA -383.16%
ROE N/A
ROIC N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESLA Yearly ROA, ROE, ROICESLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ESLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ESLA Yearly Profit, Operating, Gross MarginsESLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ESLA has more shares outstanding
  • There is no outstanding debt for ESLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ESLA Yearly Shares OutstandingESLA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
ESLA Yearly Total Debt VS Total AssetsESLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -28.62, we must say that ESLA is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -28.62, ESLA is doing worse than 86.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28.62
ROIC/WACCN/A
WACCN/A
ESLA Yearly LT Debt VS Equity VS FCFESLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

  • ESLA has a Current Ratio of 0.15. This is a bad value and indicates that ESLA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.15, ESLA is not doing good in the industry: 93.69% of the companies in the same industry are doing better.
  • ESLA has a Quick Ratio of 0.15. This is a bad value and indicates that ESLA is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ESLA has a worse Quick ratio (0.15) than 93.31% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.15
ESLA Yearly Current Assets VS Current LiabilitesESLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for ESLA have decreased strongly by -55.40% in the last year.
EPS 1Y (TTM)-55.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ESLA will show a very strong growth in Earnings Per Share. The EPS will grow by 77.03% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-132.85%
EPS Next 2Y-75.72%
EPS Next 3Y-52.45%
EPS Next 5Y77.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ESLA Yearly Revenue VS EstimatesESLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
ESLA Yearly EPS VS EstimatesESLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ESLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ESLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESLA Price Earnings VS Forward Price EarningsESLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ESLA Per share dataESLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as ESLA's earnings are expected to decrease with -52.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-75.72%
EPS Next 3Y-52.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ESLA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ESTRELLA IMMUNOPHARMA INC

NASDAQ:ESLA (2/11/2026, 4:10:08 PM)

1.3

-0.08 (-5.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)N/A
Inst Owners1.97%
Inst Owner Change-2.44%
Ins Owners2.12%
Ins Owner Change0%
Market Cap49.10M
Revenue(TTM)N/A
Net Income(TTM)-13.50M
Analysts82.86
Price Target8.16 (527.69%)
Short Float %7.39%
Short Ratio7.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS-0.26
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -383.16%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.15
Altman-Z -28.62
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-55.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.69%
EPS Next Y-132.85%
EPS Next 2Y-75.72%
EPS Next 3Y-52.45%
EPS Next 5Y77.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-503.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-503.13%
OCF growth 3YN/A
OCF growth 5YN/A

ESTRELLA IMMUNOPHARMA INC / ESLA FAQ

What is the ChartMill fundamental rating of ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to ESLA.


Can you provide the valuation status for ESTRELLA IMMUNOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to ESTRELLA IMMUNOPHARMA INC (ESLA). This can be considered as Overvalued.


How profitable is ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

ESTRELLA IMMUNOPHARMA INC (ESLA) has a profitability rating of 0 / 10.


What is the financial health of ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

The financial health rating of ESTRELLA IMMUNOPHARMA INC (ESLA) is 0 / 10.


What is the expected EPS growth for ESTRELLA IMMUNOPHARMA INC (ESLA) stock?

The Earnings per Share (EPS) of ESTRELLA IMMUNOPHARMA INC (ESLA) is expected to decline by -132.85% in the next year.